Targeting intracellular protein turnover by inhibiting the ubiquitin-proteasome pathway as a strategy for cancer therapy is a new addition to our chemotherapeutic armamentarium, and has seen its greatest successes against multiple myeloma. The first-in-class proteasome inhibitor, bortezomib, was initially approved for treatment of patients in the relapsed/refractory setting as a single agent, and was recently shown to induce even greater benefits as part of rationally designed combinations that overcome chemoresistance. Modulation of proteasome function is also a rational approach to achieve chemosensitization to other antimyeloma agents, and bortezomib has now been incorporated into the front-line setting. Bortezomib-based induction regimens are able to achieve higher overall response rates and response qualities than was the case with prior standards of care, and unlike these older approaches, maintain efficacy in patients with clinically and molecularly defined high-risk disease. Second-generation proteasome inhibitors with novel properties, such as NPI-0052 and carfilzomib, are entering the clinical arena, and showing evidence of antimyeloma activity. In this spotlight review, we provide an overview of the current state of the art use of bortezomib and other proteasome inhibitors against multiple myeloma, and highlight areas for future study that will further optimize our ability to benefit patients with this disease.
Introduction
Multiple myeloma is a neoplastic proliferation of plasma cells, 1 which normally serve as engines for the large-scale synthesis of immunoglobulins. It is perhaps both ironic and fitting, therefore, that one of the most successful therapeutics against this disease disrupts normal protein homeostasis by targeting the proteasome. As part of the ubiquitin-proteasome pathway, the proteasome is the final common effector of the vast majority of regulated intracellular proteolysis. Proteins destined for turnover are tagged with polyubiquitin chains by the ubiquitin conjugation system, which was elucidated by Nobel laureates Aaron Ciechanover, Avram Hershko and Irwin Rose. 2, 3 Target proteins are subject to turnover through the 20S and 26S proteasomes, which were characterized by Alfred Goldberg, Marian Orlowski and Martin Rechsteiner.
4-6 Each 20S particle, which also serves as the core of the 26S proteasome, contains up to five proteolytic activities, which cleave proteins after acidic, basic, branched chain, hydrophobic and small neutral amino acids, generating oligopeptides and, eventually, amino acids.
Peptide inhibitors of the proteasome were initially synthesized to probe its proteolytic functions. 7, 8 Interest in their potential as therapeutic agents was raised by later studies, which determined that they induced apoptosis in both in vitro 9, 10 and in vivo 11, 12 tumor model systems.
The emergence of multiple myeloma as a rational target for proteasome inhibition was, in part, supported by pioneering studies showing the prominent role of the transcription factor nuclear factor-kB (NF-kB) in the biology of this disease. As detailed in several excellent reviews, 13, 14 NF-kB promotes myelomagenesis by inducing growth and angiogenesis factors such as interleukin-6 and vascular endothelial growth factor, by activating important cell-cycle regulators such as c-Myc and cyclin-D1, by promoting an antiapoptotic state through intermediates such as Bcl-2 and Bcl-x L , and by enhancing myeloma cell adherence to the surrounding stroma, such as through effects on fibronectin and vascular cell adhesion molecule-1. Proteasome inhibitors suppress NF-kB activity by stabilizing the inhibitory molecule IkB, which binds NF-kB and prevents its nuclear translocation, thereby downregulating levels of its targets and producing a potent antimyeloma effect. 15 Notably, mutations that activate the canonical or non-canonical NF-kB pathway predict for a better response to bortezomib (VELCADE) therapy. 16, 17 In that the proteasome is involved in turnover of 80% or more of cellular proteins, 18 proteasome inhibition also has a number of other effects. Many of these contribute to antitumor activity, such as by stabilizing proapoptotic p53 and Bax proteins, dissipating the mitochondrial transmembrane potential and inducing release of cytochrome c, activating c-Jun-N-terminal kinase, and stimulating endoplasmic reticulum stress. The latter may be especially important, in that some studies have suggested that the large basal level of endoplasmic reticulum stress associated with high levels of immunoglobulin production makes myeloma especially sensitive to proteasome inhibitors. 19 Other effects of proteasome inhibitors appear to promote cellular survival, such as activating multiple heat-shock protein (HSP) family members, inducing the stress response protein MKP-1, and promoting activity of the protein kinase B/Akt pathway (Table 1) . 20 Fortunately, on balance, the net effect is typically a proapoptotic one, as evidenced by the findings of the first study of PS-341, now known as bortezomib, the first-in-class proteasome inhibitor to reach the clinic. 21 All nine patients with plasma-cell dyscrasias derived some benefit from therapy in this phase-I trial, including one durable complete remission (CR), which in part, set the stage for its further development.
Bortezomib in the relapsed/refractory setting
The antimyeloma activity of bortezomib was initially confirmed in two multi-center phase II trials, [22] [23] [24] [25] the larger of which, led by Richardson et al., 22 administered bortezomib at the most commonly used dose and schedule, 1.3 mg/m 2 on days 1, 4, 8 and 11 of every 21-day cycle. Among 193 evaluable patients, of whom 91% had disease that was refractory to their previous therapy, partial response (PR) or better was seen in 27%, of whom 10% achieved a CR or near-CR (nCR). Many of these patients had never been in CR previously and, indeed, achieving CR was then a rare outcome in this setting. Also of note, the median time to progression (TTP) after bortezomib was 7 months, compared with 3 months on whatever had been the previous therapy. This also was a decidedly unusual and exciting outcome in myeloma, where response durability typically decreases with successive salvage regimens. 26 Adverse events that reached at least moderate severity included thrombocytopenia, seen in 28% of patients, fatigue in 12%, peripheral neuropathy in 12% and neutropenia in 11% patients. Bortezomib-mediated thrombocytopenia and peripheral neuropathy have since been extensively characterized, with the former being predictable and transient, 27 and both being manageable and reversible. [28] [29] [30] These findings led to the approval of bortezomib by the Food and Drug Administration for relapsed/refractory myeloma in patients with at least two prior lines of therapy.
Bortezomib was then studied in a randomized phase III trial in comparison with dexamethasone targeting relapsed myeloma. 31 Toxicities were comparable to those seen in phase II, although the larger accrual and randomized design allowed for the identification of an increased, 13% risk of herpes zoster reactivation for bortezomib-treated patients. 32 This finding has been confirmed in other trials, 33 although its occurrence can be prevented with acyclovir. 34 The initially reported response rate to bortezomib was 38%, which improved to 43% with continued therapy, 35 and included CRs in 9%. These compared favorably to dexamethasone, where a PR or better was seen in only 18% of patients, with less than 1% CRs. Moreover, these improvements translated into superior durability, with a TTP of 6.22 months on bortezomib and only 3.49 months with dexamethasone. As a result, median survival improved from 23.7 months for dexamethasone to 29.8 months for bortezomib. 35 This was especially impressive in light of the fact that almost two-thirds of patients crossed over to bortezomib after a planned interim analysis showed it's superiority. On the basis of these findings, bortezomib was approved for patients with relapsed and/or refractory myeloma who had received at least one prior therapy. Moreover, these data suggested that earlier bortezomib use was associated with a greater benefit, and pointed toward its adoption into front-line therapy. Table 1 Overview of some of the molecular effects of proteasome inhibitors that contribute to their antimyeloma activity 37 can be effective. Novel toxicities have been described in a minority of patients, including tumor lysis syndrome [38] [39] [40] and pulmonary complications, 41, 42 the latter of which may be reduced with dexamethasone, 43 as well as rare skin toxicity 44 and hepatitis. 45 More common drug-related toxicities, especially thrombocytopenia and peripheral neuropathy, appear not to be cumulative, allowing for extended dosing. 46 Peripheral neuropathy may be due to accumulation of aggresomes in dorsal root ganglia, 47, 48 which may provide a mechanism-based approach to reduce its development. Other studies have suggested a possible contribution from increased tubulin polymerization and stabilization 49 and, in some cases, of immune-mediated mechanisms. 50 Bortezomib was found to be safe and effective in patients with clinically defined high-risk disease, including older patients, 51 those with elevated b 2 -microglobulin 52 and those with renal failure. [53] [54] [55] Indeed, bortezomib can be effective in contributing to a reversal of acute renal failure. [56] [57] [58] Also, bortezomib can overcome molecularly defined high-risk myeloma, especially disease characterized by deletion of chromosome 13 59 and possibly by the 4;14 translocation. 60, 61 Finally, a number of studies have shown the beneficial effects of bortezomib or bortezomib-based combinations on bone metabolism, [62] [63] [64] [65] [66] including its ability to activate osteoblasts. Indeed, one analysis suggested that increases in bone alkaline phosphatase levels were a predictor of bortezomib response. 67 
SPOTLIGHT

Bortezomib-based combination regimens
In addition to the efficacy of bortezomib as a single agent, proteasome inhibition is a rational approach to overcome chemoresistance and achieve chemosensitization. Multiple mechanisms contribute to these endpoints, including suppression of chemotherapy-mediated NF-kB activation, inhibition of maturation of the P-glycoprotein multi-drug resistance pump and induction of phosphorylation and cleavage of antiapoptotic Bcl-2 into proapoptotic fragments, among others (Table 2) . 20, 68, 69 A large number of bortezomib-based combinations have been tested pre-clinically, many of which have made their way into the clinic. Dexamethasone is one of the most common agents to be combined with bortezomib, based, in part, on pre-clinical studies showing that it increased antimyeloma activity. 15, 70 Several clinical trials have documented that dexamethasone addition improves the response rate and response quality in up to 34% of patients after a suboptimal benefit from single-agent bortezomib. 22, 71, 72 Higher response rates have also been seen when this two-drug regimen is used initially, 66, 73 as is the case for bortezomib with other corticosteroids, 37 although randomized trials comparing these have not been performed.
One regimen for which randomized data are available is bortezomib with pegylated liposomal doxorubicin (Doxil; PLD), which was designed based on studies showing that anthracyclines suppressed induction of antiapoptotic HSPs and stress response proteins. [74] [75] [76] A phase I trial showed that this regimen was tolerable and active, 77 with a greater response rate than that expected of bortezomib alone and a better response durability, with a TTP of 9.3 months. 78 These findings led to a pivotal randomized, phase III international study of bortezomib/PLD compared with bortezomib. This trial showed that addition of PLD significantly enhanced the response quality, with a 42% increase in the proportion of patients achieving a CR or very good PR (VGPR); the median duration of response, which increased from 7.0 months to 10.2; the median TTP, which rose from 6.5 to 9.3 months; 79 and showed an early trend toward an improved overall survival (OS). Bortezomib/PLD was also active in patients whose disease was refractory to other antimyeloma agents, 80 and was safe and effective in patients with renal compromise. 81 Other bortezomib-based combinations that have been studied for relapsed and/or refractory myeloma (Table 3) have included regimens incorporating alkylators, anthracyclines, HSP-90 inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Many of these have been rationally designed based on findings that proteasome inhibition suppresses DNA damage repair pathways, 70 supporting combinations with DNA damaging-agents; activates the antiapoptotic HSP and stress responses, 82, 83 as well as the pro-survival protein kinase B/Akt, 84, 85 supporting regimens with HSP inhibitors such as tanespimycin and the anti-IL-6 monoclonal antibody CNTO 328; 83 and induces aggresome formation as an alternative means to remove misfolded proteins, 86, 87 supporting the use of histone deacetylase inhibitors, which block this pathway. Studies of these regimens have generally found that bortezomib can be delivered at, or very near, its standard dose and schedule, even with the addition of other drugs, typically with little, if any, overlapping toxicities. Several of these have suggested that Table 2 Overview of additional mechanisms of action of proteasome inhibitors that add to the antimyeloma activity of other chemotherapeutics
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Target
Mechanism Consequence References
Bcl-2 Induce Bcl-2 phosphorylation and cleavage Sensitize to multiple cytotoxic agents 157, 197 DNA-PK Suppress expression, and induce cleavage, of DNA PK and other DNA damage repair enzymes Sensitize to DNA damaging agents such as alkylators and anthracyclines 70, 193 NF-kB Stabilize IkB Sensitize to multiple cytotoxic agents 70, 192 PgP Inhibit normal maturation of precursor forms of PgP
Reduce multi-drug resistance to chemotherapeutics subject to PgP 146, 198, 199 Survivin Reduce survivin levels in combination with cytotoxics Sensitize to DNA damaging drugs Abbreviations: Bcl-2, B-cell CLL/lymphoma-2; DNA-PK, DNA-dependent protein kinase; IkB, inhibitor of NF-kB; NF-kB, nuclear factor kappa B; PgP, P-glycoprotein; Topo, topoisomerase.
bortezomib-based combinations are associated with lower rates of neuropathy, 79 in some cases possibly due to decreased aggresome formation 88 in dorsal root ganglia. In addition, these studies have generally shown encouraging signs of activity, including response rates approaching 100% in some cases, 89, 90 and in others the ability to induce responses in patients whose disease was previously bortezomib-refractory. [91] [92] [93] [94] [95] Pivotal trials that could lead to regulatory approvals are underway or planned with several of these, including bortezomib with CNTO 328, perifosine, tanespimycin and vorinostat.
Bortezomib for previously chemotherapy-naïve multiple myeloma
Validation of the activity of bortezomib against myeloma quickly prompted investigators to incorporate it into the frontline setting to improve the efficacy of induction therapy. The first such study, led by Jagannath et al., 96 evaluated bortezomib alone at the relapsed/refractory dose and schedule, to which dexamethasone was added at 40 mg on each day of bortezomib therapy, and the day after, if less than a PR was achieved after two cycles. Common adverse events of at least grade 2 severity included sensory neuropathy, seen in 31% of patients, constipation in 28%, myalgias in 28% and fatigue in 25% of patients. Bortezomib alone produced an overall response rate (ORR) of 40% in 32 patients, including 12% who achieved CR or nCR, and after addition of dexamethasone, the response rate improved to 88%, including 25% with CR or nCR. Activity of the bortezomib/dexamethasone regimen was confirmed by a later phase II study, which found a response rate of 66% using lower corticosteroid doses. 97 A large number of other bortezomib-based combinations have since been evaluated ( 107 Phase III trials of these regimens are underway, or in some cases have been completed, comparing modern induction therapy with older standards of care (Table 4) . Harousseau et al. 108 have reported on their study randomizing patients to bortezomib/dexamethasone or infusional vincristine and doxorubicin with oral dexamethasone (VAD). Patients receiving Table 3 Bortezomib-based combination regimens in the treatment of relapsed and/or refractory multiple myeloma The study evaluable population is indicated in parentheses. The responders included a total of five patients, three of whom also received dexamethasone.
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bortezomib/dexamethasone had a better ORR and response quality, with 39% achieving at least VGPR, compared with only 16% after VAD. This edge was maintained after transplantation, with 61% reaching a VGPR or better if bortezomib/dexamethasone was used, versus only 44% after VAD. Moreover, since a second transplant was added to patients who did not reach a VGPR after their first transplant, more patients induced with VAD required this additional therapy. Despite this, the early follow-up data indicate a superior progression-free survival and fewer deaths among the group induced with bortezomib/ dexamethasone. Important findings have also been reported by Cavo et al. 109 who have compared bortezomib with TD (VTD) to TD. Induction therapy with VTD provided a 62% VGPR or better rate compared with only 29% for TD, and after transplantation this benefit was maintained, with 76% having VGPR or better if they started with VTD, compared with only 58% of those who had received TD. Notably, both studies found no impact on stem cell mobilization, collection and later engraftment by the addition of bortezomib, as has been the case for other pre-transplant trials. Also, both found that the bortezomib-based therapy remained superior in patients with high-risk disease, including patients with elevated b 2 -microglobulin, 108 deletion of chromosome 13, 108,109 the 4;14 translocation 109 or deletion of p53.
109
For transplant-ineligible patients, bortezomib-based therapies that have been studied include bortezomib with melphalan and prednisone (MP), 110, 111 with thalidomide and prednisone, 112 and with MP and thalidomide, 113 among others (Table 4) . Mateos et al. 110 reported the results of a phase I/II trial of bortezomib with MP (VMP), whose principal toxicities included thrombocytopenia, seen in 51% of patients, neutropenia in 43%, peripheral neuropathy in 17% and diarrhea in 16% of this older population. A response rate of 89% was noted, including 32% with immunofixation-negative CR, half of whom were also in remission by immunophenotyping. Longer term follow-up showed a median TTP of 27.2 months, which was not influenced by poor-risk features such as elevated b 2 -microglobulin or adverse cytogenetics. 111 These findings provided the rationale for an international, randomized phase III study comparing VMP with MP, which revealed the three-drug regimen induced a 71% ORR and CRs in 30%, compared with only 35 and 4%, respectively, for MP. 114 TTP was the primary study endpoint, and proved to be 24 months for VMP, compared with 16.6 months for MP, while median response duration was prolonged from 13.1 months for MP to 19.9 for VMP. Importantly, although the median OS had not been reached on either arm, a significant trend was emerging favoring VMP, with a hazard ratio of 0.64 after a median follow-up of 25.9 months.
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Bortezomib in other myeloma-related settings
A number of investigators have begun to use bortezomib or a bortezomib-based combination as a consolidation or maintenance strategy. One such study found that bortezomib/ dexamethasone after a response to salvage therapy for relapsed and/or refractory disease converted six PRs into either VGPRs or CRs, and decreased M-protein values in 11/40 patients. 115 Median TTP was 23 months with a progression-free survival of 69% at 1 year and an OS of 63% at 1 year, although four patients died of infectious complications. Another trial focused on high-risk patients who received both induction with bortezomib as a single agent, providing a 48% PR rate, and then followed this with maintenance bortezomib, which upgraded one patient to a CR. 116 Among 15 patients who received maintenance, the median progression-free survival was 19.8 months, although, notably, among seven who progressed on maintenance and were re-induced with bortezomib, none responded.
In the transplant setting, several investigators have evaluated incorporating bortezomib into the conditioning regimen. At the University of Arkansas, bortezomib was dosed at 1.0-1.3 mg/m 2 on days À4 and À1 prior to melphalan, which was administered at up to 250 mg/m 2 in fractionated doses. 117 This approach was safe, with non-hematologic toxicities of at least grade 3, including mucositis, diarrhea, febrile neutropenia, pneumonia/ sepsis and fatigue. Of 27 evaluable patients, which consisted of a high-risk population with poor-risk cytogenetic features and up to 75% having had prior transplantation, PR was obtained in 9 (39%), including 6 (26%) who achieved CR. Another study focusing on high-risk patients treated those with primary refractory myeloma and plasma-cell leukemias with two cycles of bortezomib, then high-dose melphalan and bortezomib conditioning, and finally tandem transplantation. 118 No doselimiting toxicities were seen and an ORR of 90% was noted, including 53% in VGPR or better. In lower risk patients with relapsed myeloma, bortezomib provided an even higher VGPR or better rate of 87% in 15 patients. 119 More intense dosing of bortezomib was studied by L'Intergroupe Francophone du Myelome who added 1.0 mg/m 2 of bortezomib on days À6, À3, þ 1 and þ 4 to high-dose melphalan on day À2.
120 Among 57 patients this resulted in mucositis in 39%, erythroderma in 30%, headache in 20%, hallucinations in 9% and grade-2 peripheral neuropathy in three cases, as well as five serious adverse events, including pulmonary embolism in one patient, seizure in one, acute cholecystitis in one and two cases of pneumonia. Twenty patients (36%) achieved CR and another 17 (30%) achieved VGPR, and further studies of this regimen are planned. Importantly, the impact of bortezomib scheduling may require further study, since one trial evaluated giving bortezomib 24 h before or after high-dose melphalan. 121 While there were no differences in toxicities or engraftment, bortezomib after melphalan produced higher levels of apoptotic indexes in the marrow, suggesting the possibility of a greater myeloma cell kill.
Greater experience has been garnered using bortezomib in maintenance or consolidation after prior transplantation. One common finding is that bortezomib produced a higher rate of reactivation of herpes zoster [122] [123] [124] [125] [126] than in the relapsed and/or refractory setting, indicating a definite need for prophylaxis. Several single-arm studies have shown that bortezomib produced high ORRs, 123, 125, 127 an improvement in response quality 124, 126 and increased progression-free survival. 123, 125, 127 In one notable trial, 62 patients received induction therapy with VAD, followed by VTD, and then bortezomib maintenance after autologous transplantation. Complete remission or nCR was seen in 68% of patients, who had a 98% 1-year OS. 127 Another interesting approach applied VTD as a consolidation in 40 patients who were in CR or VGPR after transplantation, and were thalidomide-and bortezomib-naïve. 128 Six converted into a molecular remission based on studies of an immunoglobulin heavy chain gene rearrangement. Notably, none showed evidence of clinical relapse with a median follow-up of 26 months, whereas eight relapses were seen in the group that did not achieve molecular remission with a median of 12 months.
Control of graft-versus-host disease (GVHD) may be another potential application for bortezomib. This is supported by preclinical studies showing bortezomib's ability to inhibit in vitro mixed lymphocyte responses and promote apoptosis of alloreactive T cells, resulting in protection from acute GVHD without reducing graft-versus-leukemia effects. 129 Interestingly, this depended on the timing of bortezomib administration and was seen if it was given immediately after transplantation, 129 whereas delayed administration exacerbated GVHD. 130 The latter is supported by clinical data from one report showing mild aggravation of existing acute or chronic GVHD in several patients, and appearance of de novo GVHD in one, when bortezomib was used after allogeneic transplantation. 126 Other studies, however, have reported that bortezomib could be safely given after prior allografting without exacerbating GVHD, and showed the ability to improve survival in responding patients, 131 and to even control chronic GVHD. 132 Retreatment with, and resistance to, bortezomib
The incorporation of bortezomib into the up-front setting will provide significant benefits to patients requiring induction chemotherapy. However, most of the data in the relapsed and/ or refractory setting were obtained from bortezomib-naïve patients, and these findings may, therefore, be less applicable to cohorts that have been previously proteasome inhibitorexposed. Fortunately, there are some data on retreatment of patients who have been bortezomib-exposed previously. One retrospective study of 22 patients who had achieved a 68% response rate with bortezomib alone or with dexamethasone on the phase II or phase III trials targeting relapsed and/or refractory disease, found that retreatment produced a 50% response rate. 133 A second, larger, study of 82 patients who had achieved an initial response rate of 59% found that retreatment induced a 22% ORR. 134 Notably, patients who had achieved at least a VGPR previously were more likely to respond on re-challenge, and had a 44% response rate. An interesting approach may be to start with bortezomib alone, and then add other drugs, such as dexamethasone, or MP, if the response is less than brisk, which resulted in a 73% response rate in one study. 135 While retreatment, especially with combination regimens, appears to be an attractive option, the decreased response rate SPOTLIGHT seen on re-challenge indicates the emergence of resistance. Elucidation of these mechanisms is an important goal to identify approaches to subvert them and re-sensitize myeloma to bortezomib, and to possibly find approaches to prevent them from arising altogether. Early reports indicate that increased and/ or altered proteasome subunit expression may play a role. 136, 137 This appears to be especially the case for the b 5 -proteasome subunit, which contains the chymotrypsin-like activity and is the major target for bortezomib. Its overexpression [137] [138] [139] and mutation 139, 140 has induced bortezomib resistance in several in vitro-derived models, and studies to determine if similar mechanisms may be relevant in the clinical arena are underway. These findings suggest that proteasome inhibitors that bind irreversibly, and/or to a greater number of proteasome subunits with a more profound impact on proteolysis, could be of interest. Some support has been obtained for this in studies of NPI-0052 141 and carfilzomib, 142 both of which are irreversible inhibitors that have overcome bortezomib resistance in preclinical models. Other investigators have reported the presence in primary cells of proteasome inhibitor-resistant pathways of NF-kB activation, 143, 144 suggesting that combination regimens with other strategies to suppress NF-kB, such as with IkB kinase inhibitors, 145 may prove fruitful. Finally, knockdown of multidrug resistance mechanisms, including the P-glycoprotein, 146 and mitochondria-mediated antiapoptotic pathways, 147 have also been noted to overcome bortezomib resistance pathways, providing many attractive avenues for further research.
Interactions between bortezomib and dietary supplements
Most proteasome inhibitors are based on peptides, which serve as active-site analogs that bind the proteasome subunits, and also contain a chemical entity, or 'warhead,' which binds to the active-site threonine. Julian Adams 148, 149 presciently selected boronic acid as the bortezomib warhead due to its ability to greatly enhance potency and specificity in comparison with older agents such as peptidyl aldehydes. However, boronates also interact with compounds that contain 1,2-or 1,3-diols to form cyclic moieties 150 in which the boronic acid is no longer free to bind the proteasome. Consistent with this possibility, vitamin C, a 1,2-diol, has been described to bind and inactivate bortezomib, thereby reducing its pre-clinical anticancer activity. 151 Similarly, epigallocatechin gallate, a polyphenolic green tea component, has comparable capabilities. 152 These findings have led to recommendations that patients receiving bortezomib should limit their intake of vitamin C, epigallocatechin gallate and related antioxidants. 153 This advice is likely to be especially applicable for patients who take pharmacological doses of such supplements, 154, 155 highlighting the importance for healthcare providers to make a careful and regular inventory of the agents being used by their patients. Finally, any maneuvers that increase reactive oxygen species levels could contribute to oxidative deboronation of bortezomib mediated by cytochrome P450, 156 and, therefore, potentially reduce antimyeloma activity, although this could be negated by the proapoptotic activities of reactive oxygen species. 157 Notably, proteasome inhibitors with different chemistries, such as epoxyketones, would be expected to not be affected in this manner. 153 
Novel proteasome inhibitors
With validation of the proteasome as a target for myeloma therapy, interest was enhanced in the development of inhibitors that could have novel, attractive features. A number of such agents have been validated in the pre-clinical setting, most notably NPI-0052 141, 158 and carfilzomib. 142, 159 NPI-0052, also known as salinosporamide A, is related to one of the first proteasome inhibitors identified in nature, lactacystin. 160 This agent was found to bind irreversibly to the subunits responsible for the chymotryptic and tryptic proteasome activities, thereby inducing apoptosis through activation of caspase-8 with enhanced potency compared with bortezomib. 141 Perhaps due to these properties, NPI-0052 was able to overcome bortezomib resistance and, interestingly, acted synergistically with bortezomib. 158 Preliminary findings of a phase-I study of this agent targeting myeloma patients have shown it to be well tolerated using weekly intravenous injection for three consecutive weeks out of four. 161 Toxicities were comparable to those of bortezomib, but notable for an apparent lack of neurotoxicity, although one patient did develop reversible renal insufficiency. Stable disease was seen as the best response in several patients with previously progressing myeloma, and further studies are underway.
Carfilzomib is a peptide epoxyketone derived from epoxomicin, 162 which, like NPI-0052, binds irreversibly to the chymotrypsin-like activity, and may be more proteasome-targeted than bortezomib. 163 Preclinical studies showed that carfilzomib was more potent in its ability to induce caspase-8 and caspase-9 than bortezomib, and could overcome bortezomib resistance in cell line and primary plasma cell models. 142 Moreover, carfilzomib could be dosed on consecutive days in pre-clinical in vivo models without enhanced toxicity, and proteasome inhibition in excess of 80% could be achieved, 159 distinguishing this agent from bortezomib. Starting with the hypothesis that carfilzomib could, therefore, achieve more prolonged, and perhaps more profound, proteasome inhibition, and that this could result in enhanced efficacy, two phase I studies targeting B-cell-derived malignancies have now been completed. One of these used a regimen of daily dosing on five consecutive days followed by nine days off, 164 while the other dosed carfilzomib daily on two days for three consecutive weeks, followed by 12 days off. 165 The maximum tolerated dose for the five-consecutive-day regimen proved to be 15 mg/m 2 , with dose-limiting toxicities consisting of febrile neutropenia and grade 4 thrombocytopenia, while other grade 3 to grade 4 events were primarily hematologic. Stable disease or better was achieved by six myeloma patients, including one who experienced PR after previously having bortezomib-refractory disease. 164 When carfilzomib was dosed on days 1, 2, 8, 9, 15 and 16 every 28 days, the maximum tolerated dose was 20 mg/m 2 , with a hypoxic event noted as the dose-limiting toxicity (DLT) above this level. In addition, three of five patients dosed at 27 mg/m 2 experienced increase in creatinine of up to grade 2 severity that was typically associated with rapid decline in the monoclonal protein, but without evidence of tumor lysis syndrome, and which did not recur after repeat dosing. Four myeloma patients achieved at least PR, 165 including some whose disease had previously been refractory to bortezomib-based combinations.
Phase II studies of carfilzomib are currently underway using the latter dosing schedule targeting patients with relapsed and refractory 166 or refractory myeloma. 167 In the former group, common adverse events included fatigue, nausea, upper respiratory tract infection and diarrhea, while worsening of hematologic parameters was predominantly of grade 1 or grade 2 severity. Increased creatinine level was seen in 15/46 patients, including four with acute renal failure, which in some patients may have been associated with tumor lysis, but led to dose discontinuation in only three patients. Among 39 evaluable SPOTLIGHT patients, all of whom had received prior bortezomib, 10 (26%) achieved at least a minor response or better, including five with PRs, and sixteen additional patients had stable disease. 166 In relapsed patients, non-hematologic and hematologic toxicities were similar, and increased creatinine levels were seen in five patients (16%), with two cases of possible tumor lysis that led to one patient discontinuing therapy and one death. 167 Of note, after modification of both trials to incorporate tumor lysis prophylaxis, renal events have become rare. Also, despite a high rate of baseline neuropathy in both patient populations, reports of worsening neuropathic symptoms were uncommon. Carfilzomib was active in patients with bortezomib-naïve disease, inducing PR or better in at least 54% of 13 evaluable patients, including one CR, and also in bortezomib-exposed patients, among whom 3/16 (19%) achieved PR. TTP was 169 days in the latter group, and the median had not yet been reached for the former.
Conclusions and future directions
Inhibition of the proteasome as a strategy against multiple myeloma has revolutionized the care of patients afflicted with this malignancy, and has contributed significantly to the increasing OS that is now seen in comparison with historical controls. 168, 169 Use of bortezomib, the first-in-class proteasome inhibitor, as a single agent and with dexamethasone is a standard of care and a widely accepted strategy, respectively, against relapsed and/or refractory myeloma. The regimen of bortezomib with PLD has been validated in a phase III trial as being superior to bortezomib alone, and other pivotal trials of bortezomib-based combinations are underway (Table 5) . Thus, it is very likely that, in the near future, we will have several doublet regimens to select from in the relapsed and/or refractory setting. Studies will then be needed comparing these combinations to determine their relative risks and benefits, and to evaluate the possibility that baseline molecular aspects of each patient's disease would help to predict which could be most effective. Bortezomib has now been moved into the up-front setting, and received regulatory approval as an induction therapy in combination with MP for transplant-ineligible patients. Moreover, completed and ongoing studies (Table 5) in transplant-eligible populations will probably lead to additional approvals by proving bortezomib-based therapies to be superior to previous standards such as VAD and TD. Attractive features of bortezomib in all these settings include its efficacy and safety in clinically and molecularly defined high-risk disease, its beneficial effects on bone metabolism and especially its ability to augment the efficacy of other antimyeloma agents in an additive to synergistic manner with an acceptable toxicity profile.
Despite these advances, much remains to be learned about the role of proteasome inhibitors in multiple myeloma. Bortezomib has been shown to be safe for consolidation or Proteasome inhibitors in myeloma JJ Shah and RZ Orlowski maintenance after prior standard-or high-dose therapy, for incorporation into pre-transplant conditioning and for treatment of GVHD. However, appropriately powered, randomized studies with long-term follow-up are needed to validate the early parameters of efficacy that have been obtained. Of greatest concern is the possibility that, with the use of bortezomib-based induction therapy, patients at relapse will have disease that is less responsive to re-challenge with bortezomib-containing combinations. Early studies of retreatment strategies after prior therapy of relapsed/refractory disease (Table 6 ) are somewhat reassuring in that they show that there is definitely a subgroup of patients who can benefit from the reuse of bortezomib. Moreover, it is possible that in a first-relapse setting, myeloma will be more responsive to bortezomib-based therapy after induction with bortezomib than is the case in the relapsed/ refractory setting, where patients have received multiple prior lines of therapy. Some support for this is provided by initial data of the results of bortezomib use in the salvage setting after prior induction with VMP, 170 showing that the overall and CR rates are comparable to those seen in the bortezomib-naïve relapsed/ refractory setting. Again, however, appropriately powered, randomized studies with long-term follow-up will be needed to validate these approaches. Moreover, the fact that response rates at re-challenge in patients with previously bortezomibsensitive disease are typically lower than in the previous line, indicates the emergence of resistance to bortezomib in at least a subpopulation. A greater understanding of the mechanisms behind this phenomenon at the clinical level is urgently needed to help identify strategies that may be successful in overcoming such resistance. Since multiple mechanisms are likely to contribute to this phenotype, by studying which pathways are activated in their particular myeloma, it may be possible to individualize therapy for such patients. In that bortezomib in combination with Akt, 91 histone deacetylase 94, 171 or HSP-90 93 inhibitors has in some cases been effective in patients with previously bortezomib-refractory disease, it is possible that we already have some of the necessary agents at our disposal to resensitize myeloma to bortezomib. Another successful approach in this setting may be to switch to a different proteasome inhibitor, in analogy with data on the use of immunomodulatory agents against myeloma, [172] [173] [174] which show that, for example, lenalidomide can be effective despite prior thalidomide use. 175 Encouraging pre-clinical data have been obtained in this regard with NPI-0052 and carfilzomib, which utilize different chemistries than bortezomib, bind the proteasome irreversibly and may inactivate more proteasome activities in vivo. Both of these have entered clinical trials and are showing good tolerability, as well as early suggestions that they may induce a lower rate of peripheral neuropathy. Carfilzomib in particular, which has advanced further in development, is showing encouraging activity as a single agent in both bortezomib-naïve and bortezomib-exposed populations. However, the former have generally shown better response rate, supporting the possibility that there may be at least some cross-resistance between all proteasome inhibitors. Moreover, as is the case for bortezomib, combination regimens based on carfilzomib and NPI-0052 will probably prove most effective against myeloma. It is likely that additional proteasome inhibitors with novel properties may yet find applicability as part of our chemotherapeutic armamentarium against multiple myeloma. Several inhibitors that will be dosed using the oral route are now entering the clinical arena, including both boronic acid 176, 177 and epoxyketone-based agents. 178 Also, immunoproteasome-specific inhibitors 179 that would be likely to have less associated non-hematologic toxicity due to the relatively restricted expression of the immunoproteasome subunits to hematopoietic tissues, may represent another attractive class of agents. In conclusion, it is likely that proteasome inhibitors will form an increasingly important part of our attack against multiple myeloma, and will contribute prominently to our ultimate endpoint of curing patients of this malignancy.
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